Celadon Pharmaceuticals PLC Cash Flow-to-Debt Ratio
Celadon Pharmaceuticals PLC cash flow-to-debt ratio. Celadon Pharmaceuticals PLC (CEL) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2024, meaning its operating cash flow of GBX-1.29 Million could theoretically repay 0% of its total liabilities (GBX6.01 Million) in one year. See Celadon Pharmaceuticals PLC financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Celadon Pharmaceuticals PLC (2019–2023)
Cash flow-to-debt ratio of Celadon Pharmaceuticals PLC from 2019 to 2023. Historical debt coverage capacity for Celadon Pharmaceuticals PLC across 5 annual periods. Check Celadon Pharmaceuticals PLC (CEL) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Celadon Pharmaceuticals PLC Cash Flow-to-Debt Ratio by Year (2019–2023)
Celadon Pharmaceuticals PLC cash flow-to-debt ratio by year from 2019 to 2023. Year-by-year debt coverage analysis for Celadon Pharmaceuticals PLC. For the full cash flow conversion analysis, see Celadon Pharmaceuticals PLC cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2023 | -0.99x | GBX-5.97 Million | GBX6.04 Million | ▼ -0.7% |
| 2022 | -0.98x | GBX-6.10 Million | GBX6.21 Million | ▲ +93.8% |
| 2021 | -15.96x | GBX-3.15 Million | GBX197.23K | ▼ -77099.1% |
| 2020 | -0.02x | GBX-77.57K | GBX3.75 Million | ▼ -2815.9% |
| 2019 | 0.00x | GBX1.98K | GBX2.60 Million | — |